Shots:

• GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines- which were jointly developed by GTS and Fuso Pharmaceutical
• The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share in ophthalmologic diseases
• The companies will partner with others to jointly promote drug development- non-clinical studies- clinical studies- manufacturing and approvals- sales- etc. and create a business structure for commercialization of the product

Click here to­ read full press release/ article | Ref: GTS | Image: Kabu Fx Trends